Post-earnings recap
Reported
Thu, Feb 19, 2026
EPS actual
$-2.57
EPS est.
$0.04
EPS surprise
-7442.86%
1-day move
-11.11%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Madrigal Pharmaceuticals reported a significant loss per share, which disappointed investors and led to an 11.11% drop in stock price. The lack of revenue data and guidance adds to the uncertainty surrounding the company's future performance. Investors may be concerned about the company's ability to navigate its current challenges without clear direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-2.57 | N/A | -7442.86% |
| Revenue | N/A | N/A | N/A |
Management's tone was defensive, reflecting the company's current challenges. There was no forward guidance provided, leaving investors uncertain.
Management did not provide specific guidance for future quarters.
The company acknowledged challenges but did not elaborate on strategies.